Overview

Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

This trial will evaluate whether the sequential administration of Cisplatin/Vinorelbine/Bevacizumab followed by Docetaxel/Gemcitabine/Bevacizumab versus the Cisplatin/Docetaxel/Bevacizumab combination as first line treatment offers a survival advantage in patients with locally advanced or metastatic NSCLC.

Phase:

Phase 2

Details

Lead Sponsor:

Hellenic Oncology Research Group

Collaborator:

University Hospital of Crete

Treatments:

Bevacizumab
Cisplatin
Docetaxel
Gemcitabine
Vinblastine
Vinorelbine